ArticleMetabolic brain disease2021
Protective mechanism of Syringic acid in an experimental model of Parkinson's disease.
Article in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Antinociceptive and Anti-Inflammatory Effects of Syringic Acid:ACS omega · 2026Article
- Syringic Acid in Health and Disease: Mechanisms, Biological Activities, and Future Perspectives.International journal of molecular sciences · 2026Review
- Synthesis, Antidepressant-like and Anxiolytic-like Effects of Novel Thiadiazole Derivatives: Behavioral Assessment and Mechanistic Investigation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Protective effects of Syringic acid on joint inflammation and damage in a rat model of rheumatoid arthritis.Clinical rheumatology · 2026Article
- In silico and in vitro insights into the wound-healing potential of syringic acid: protective and regenerative effects on human fibroblasts.BMC pharmacology & toxicology · 2026Article
- Neuroprotective mechanism of syringic acid targeting oxidative damage and neuroinflammation in an experimental model of traumatic brain injury.Inflammopharmacology · 2026Article
- Syringic Acid as a Potential Anticonvulsant Agent: Mechanistic Perceptions into Nitrite and Oxidative Stress Balance in the Prefrontal Cortex.Current pharmaceutical design · 2026Article
- Investigating the therapeutic potential of transcranial direct current stimulation in an experimental Parkinson's model through glutamate pathway.Brain structure & function · 2025Article
- Smooth pursuit eye movements in different directions and frequencies as biomarkers for detecting early stage Parkinson's disease and assessing levodopa responsiveness: a cross-sectional study.European journal of medical research · 2025Observational
- Neuromotor rehabilitation in Parkinsonian syndromes: outcomes and disability after hip fracture.European journal of medical research · 2025Article
- Navigating the Deep Eutectic Solvent Landscape: Experimental and Machine Learning Solubility Explorations of Syringic, p-Coumaric, and Caffeic Acids.International journal of molecular sciences · 2025Article
- Investigating the relationship between glymphatic dysfunction and motor symptoms in Parkinson's disease.European journal of medical research · 2025Article
- Association between red cell distribution width/serum albumin ratio and Parkinson's disease.European journal of medical research · 2025Article
- Mathematical and Dynamic Modeling of the Anatomical Localization of the Insula in the Brain.Neuroinformatics · 2025Review
- Natural polyphenols as novel interventions for aging and age-related diseases: Exploring efficacy, mechanisms of action and implications for future research.Chinese herbal medicines · 2025Review
- Evaluation of the antinociceptive effects of syringic acid in male mice: Using formalin, writhing, and hot plate pain models.Current journal of neurology · 2025Article
- Adropin exerts neuroprotection in an experimental rat model of Parkinson's disease.Iranian journal of basic medical sciences · 2025Article
- 1-Nitro-2-phenylethane: a promising phytoconstituent to modulate neuroinflammation and oxidative stress with repercussions on neurological and psychiatric disorders.Frontiers in pharmacology · 2025Review
- Unveiling the antioxidant and anti-inflammatory potential of syringic acid: mechanistic insights and pathway interactions.Frontiers in pharmacology · 2025Review
- Physiological Mechanisms by Which the Functional Ingredients in Beer Impact Human Health.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
6-Hydroxydopamine (6-OHDA) is a widely used chemical to model Parkinson's disease (PD) in rats. Syringic acid (SA) is a polyphenolic compound which has antioxidant and anti-inflammatory properties. The present study aimed to evaluate the neuroprotective role of SA in a rat model of 6-OHDA-induced PD. Parkinson's disease was created by injection of 6-OHDA into the medial forebrain bundle via stereotaxic surgery. Syringic acid was administered daily by oral gavage, before or after surgery. All groups were tested for locomotor activity, rotarod performance and catatony. Dopamine levels in SN were determined by an optimized multiple reaction monitoring method using ultra-fast liquid chromatography coupled with tandem mass spectrometry (MS/MS). The immunoreactivities for tyrosine hydroxylase (TH) and inducible nitric oxide synthase (iNOS) were detected by immunohistochemistry in frozen substantia nigra (SN) sections. Nitrite/nitrate levels, iNOS protein, total oxidant (TOS) and total antioxidant (TAS) status were assayed in SN tissue by standard kits. Motor dysfunction, impaired nigral dopamine release, increased iNOS expression and elevated nitrite/nitrate levels induced by 6-OHDA were significantly restored by SA treatment. Syringic acid significantly improved the loss of nigral TH-positive cells, while increasing TAS capacity and reducing TOS capacity in SN of PD rats. These data conclude that SA is a potential therapeutic agent for the treatment of 6-OHDA-induced rat model of PD. Syringic acid reduced the progression of PD via its neuroprotective, antioxidant and anti-inflammatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.